Top

European Radiology

Published in:

01-04-2014 | Experimental

Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease

Authors: Ying Ding, Sheng-Xiang Rao, Tao Meng, Caizhong Chen, Renchen Li, Meng-Su Zeng

Published in: European Radiology | Issue 4/2014

Abstract

Objectives

This study evaluates the value of Gd-EOB-DTPA-enhanced MRI for diagnosis and staging of non-alcoholic fatty liver disease (NAFLD) in an animal model by T₁ relaxation time measurement.

Methods

Thirty-four rabbits were divided into the control group (n = 10) and NAFLD group, which was split into four groups (n = 6) with a high-fat diet for an interval of 3 weeks. A dual flip angle was performed before and at the hepatobiliary phase (HBP). T₁ relaxation times of the liver parenchyma and the decrease rate (∆%) were calculated. Histological findings according to semi-quantitative scoring of steatosis, activity and fibrosis were the standard of reference.

Results

HBP and ∆% T₁ relaxation time measurement showed significant differences between normal and NAFLD groups, between non-alcoholic steatohepatitis (NASH) and NAFLD without NASH (p = 0.000–0.049), between fibrosis groups (p = 0.000–0.019), but no difference between F1 and F2 (p = 0.834). The areas under the receiver operating characteristic curves (AUCs) of T₁ relaxation time for HBP and ∆% were 0.86–0.93 for the selection of NASH and activity score ≥2, and 0.86–0.95 for the selection of F ≥ 1, 2, 3. No significant difference was found for diagnostic performance between HBP and ∆% T₁ relaxation time.

Conclusions

HBP T₁ relaxation time measurement of Gd-EOB-DTPA-enhanced MRI was useful to evaluate NAFLD according to the SAF score. HBP T₁ relaxation time measurement was as accurate as ∆% T₁ relaxation time.

Key Points

• Gd-EOB-DTPA-enhanced MRI could give useful information on NAFLD.

•HBP T ₁ relaxation time measurement was useful for the evaluation of NAFLD.

• HBP T ₁ relaxation time measurement was as accurate as ∆%.

Brunt EM (2010) Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7:195–203PubMedCrossRef

Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321PubMedCrossRef

Bedossa P, Poitou C, Veyrie N et al (2012) Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:1751–1759PubMedCrossRef

Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN (2010) PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52:904–912PubMedCentralPubMedCrossRef

Sanyal A, Poklepovic A, Moyneur E, Barghout V (2010) Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 26:2183–2191PubMedCrossRef

Ekstedt M, Franzen LE, Mathiesen UL et al (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865–873PubMedCrossRef

Miele L, Forgione A, Gasbarrini G, Grieco A (2007) Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res 149:114–125PubMedCrossRef

Dowman JK, Tomlinson JW, Newsome PN (2011) Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 33:525–540PubMedCentralPubMedCrossRef

Sofue K, Tsurusaki M, Tokue H et al (2011) Gd-EOB-DTPA-enhanced 3.0-T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma. Eur Radiol 21(11):2336–2343PubMedCrossRef

10.

Sun HY, Lee JM, Shin CI et al (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (<2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 45:96–103PubMedCrossRef

11.

Ichikawa T, Saito K, Yoshioka N et al (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45:133–141PubMedCrossRef

12.

Zech CJ, Herrmann KA, Reiser MF et al (2007) MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 6:43–52PubMedCrossRef

13.

Pascolo L, Cupelli F, Anelli PL et al (1999) Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun 257:746–752PubMedCrossRef

14.

Tsuda N, Okada M, Murakami T (2007) Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42:242–247PubMedCrossRef

15.

Wu Z, Matsui O, Kitao A et al (2013) Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis. J Magn Reson Imaging 37:1137–1143PubMedCrossRef

16.

Sonoda A, Nitta N, Ohta S et al (2011) The possibility of differentiation between nonalcoholic steatohepatitis and fatty liver in rabbits on Gd-EOB-DTPA-enhanced open-type MRI scans. Acad Radiol 18:525–529PubMedCrossRef

17.

Tsuda N, Okada M, Murakami T (2010) New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 73(1):137–142PubMedCrossRef

18.

Tsuda N, Matsui O (2011) Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression. Eur Radiol 21(12):2542–2550PubMedCrossRef

19.

Katsube T, Okada M, Kumano S et al (2011) Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 46:277–283PubMedCrossRef

20.

Katsube T, Okada M, Kumano S et al (2012) Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. Eur J Radiol 81:1460–1464PubMedCrossRef

21.

Materne R, Smith AM, Peeters F et al (2002) Assessment of hepatic perfusion parameters with dynamic magnetic resonance imaging. Magn Reson Med 47:135–142PubMedCrossRef

22.

DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRef

23.

Motosugi U, Ichikawa T, Oguri M et al (2011) Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 29(8):1047–1052PubMedCrossRef

24.

Watanabe H, Kanematsu M, Goshima S et al (2011) Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging–preliminary observations. Radiology 259(1):142–150PubMedCrossRef

25.

Yamada A, Hara T, Li F et al (2011) Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 260(3):727–733PubMedCrossRef

26.

Dahlqvist Leinhard O, Dahlström N, Kihlberg J et al (2012) Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol 22(3):642–653PubMedCrossRef

27.

Horsthuis K, Nederveen AJ, de Feiter MW et al (2009) Mapping of T1-values and Gadolinium-concentrations in MRI as indicator of disease activity in luminal Crohn’s disease: a feasibility study. J Magn Reson Imaging 29(2):488–493PubMedCrossRef

28.

Deoni SC, Rutt BK, Peters TM (2003) Rapid combined T1 and T2 mapping using gradient recalled acquisition in the steady state. Magn Reson Med 49(3):515–526PubMedCrossRef

29.

Yoshimura N, Saito K, Saguchi T et al (2013) Distinguishing hepatic hemangiomas from metastatic tumors using T1 mapping on gadoxetic-acid-enhanced MRI. Magn Reson Imaging 31(1):23–27PubMedCrossRef

30.

Fisher CD, Lickteig AJ, Augustine LM et al (2009) Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 613(1–3):119–127PubMedCentralPubMed

31.

Schwenzer NF, Springer F, Schraml C et al (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51(3):433–445PubMedCrossRef

Title: Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease
Authors: Ying Ding
Sheng-Xiang Rao
Tao Meng
Caizhong Chen
Renchen Li
Meng-Su Zeng
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 4/2014
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-014-3096-y

At a glance: The STEP trials

Springer Medicine

Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease

Abstract

Objectives

Methods

Results

Conclusions

Key Points

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 4/2014

Imaging aspects of the diagnosis of sarcoidosis

Image quality assessment of ultra low-dose chest CT using sinogram-affirmed iterative reconstruction

The role of diffusion-weighted MR imaging for differentiating benign from malignant bile duct strictures

Diagnostic value of pelvic enthesitis on MRI of the sacroiliac joints in spondyloarthritis

Efficacy of liver parenchymal enhancement and liver volume to standard liver volume ratio on Gd-EOB-DTPA-enhanced MRI for estimation of liver function

Wall morphology, blood flow and wall shear stress: MR findings in patients with peripheral artery disease